Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol).

about

Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use.Incidence and prevalence of cardiovascular disease in English primary care: a cross-sectional and follow-up study of the Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC)

P2860

Q36316732-9675BF37-4AAB-4352-A5A7-C3ECD8920740 Q58736209-743B383C-5122-4959-AEB7-A5D22E769922

P2860

Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol).

Item

http://www.wikidata.org/entity/Q37737454

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 30 January 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Sodium-Glucose Co-Transporter- ...... al World Use (Study Protocol).

@en

Sodium-Glucose Co-Transporter-2

@nl

type

Item

label

Sodium-Glucose Co-Transporter- ...... al World Use (Study Protocol).

@en

Sodium-Glucose Co-Transporter-2

@nl

prefLabel

Sodium-Glucose Co-Transporter- ...... al World Use (Study Protocol).

@en

Sodium-Glucose Co-Transporter-2

@nl

P1476

Sodium-Glucose Co-Transporter- ...... al World Use (Study Protocol).

@en

P2093

Andrew McGovern

http://www.w3.org/2001/XMLSchema#string

Michael Feher

http://www.w3.org/2001/XMLSchema#string

Neil Munro

http://www.w3.org/2001/XMLSchema#string

P2860

Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action

The use of routinely collected computer data for research in primary care: opportunities and challenges.

Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial.

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial.

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes.

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.

Royal College of General Practitioners Research and Surveillance Centre (RCGP RSC) sentinel network: a cohort profile.

A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment

P2888

s13300-017-0229-8

P304

355-363

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1007/S13300-017-0229-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Simon de Lusignan

P577

2017-01-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28138853

http://www.w3.org/2001/XMLSchema#string

P921

glucose

P932

5380492

http://www.w3.org/2001/XMLSchema#string

Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol).

about

P2860

P2860

Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol).

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932